Under the terms of the agreement, WuXi will receive $40M up front & is eligible for up to $1.46B in research, development, regulatory & commercial milestones along with undisclosed tiered royalties
GSK received the worldwide rights to research, develop, manufacture & commercialize a preclinical bispecific Ab that targets TAA on tumor cells & CD3 expression on T cells for the treatment of cancer. GSK also has an option for 3 additional discovery staged bi-/multi-specific TCE Ab
The agreement validates WuXi’s CD3 platform & WuXiBody platform which assembles mAb sequence pairs into bispecific constructs whereas GSK aims to enhance its oncology portfolio of tumor cell targeting agents
Ref: PRNewswire | Image: WuXi Biologics
Related News:- WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China
